Immuneering

Q2 FY2026 EarningsQ2 FY2026 results were slightly better than consensus on the bottom line, with a net loss of $17.3M vs. the $17.6M anticipated. Diluted EPS of -$0.27 narrowly missed the -$0.2686 consensus due to a significantly higher share count compared to the prior year. The primary driver of the variance was higher-than-expected operating expenses, particularly R&D ($14.0M) as the Phase 3 MAPKeeper 301 trial scales. Management provided strong visibility with a cash runway extended into 2029.